Position
D. E. Shaw & Co., Inc. in Entrada Therapeutics, Inc.
Back to the book · All holders of TRDA
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $156.5K$10.28 → $12.62
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 66.9K | $687.5K | — | — | — | 0.0% |
| Q1 2026 | 79K | $997.6K | $12.62 | $156.5K | $153.6K | 0.0% |